Comments
The contentious Special 301 report where the US rates its trading partners on their IP (intellectual property) track record is slated to come out by the end of April. As much as countries try to play it down as a report reflecting the US perspective, trade associations and lobby groups take a serious note of the report as it provides them ammunition to elbow their way into other markets during trade negotiations. India does not get a favourable report due to efforts taken to keep medicines affordable for the local population. And that includes an amended Patent Law that does not allow patents on changes made to an existing drug, unless it shows greater efficacy. This year’s report too will be watched by the domestic pharma industry as it will reflect the thinking of the Trump administration.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.